Back to Search
PHILIP BONOMI M.D.
M.D.
Medical Oncology Physician
NPI: 1235198573Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
Research & Publications (20)
Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer.
PMID 17428162·Expert Rev Anticancer Ther·2007
6-review
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
PMID 17671150·Clin Cancer Res·2007
6-review
Current strategies in the management of lung cancer.
PMID 16425520·Oncology (Williston Park)·2005
8-other
Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer.
PMID 15555216·Clin Lung Cancer·2004
6-review
Erlotinib: a new therapeutic approach for non-small cell lung cancer.
PMID 12882624·Expert Opin Investig Drugs·2003
6-review
New approaches to symptom improvements in lung cancer patients.
PMID 14565513·Lung Cancer·2003
6-review
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
PMID 12867061·Lung Cancer·2003
6-review
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
PMID 14717024·Am J Health Syst Pharm·2003
8-other
Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer.
PMID 11894017·Semin Oncol·2002
6-review
Chemoradiation in locally advanced non-small cell lung cancer.
PMID 11224987·Cancer Treat Res·2001
4-observational
Novel approaches for the treatment of non-small cell lung cancer.
PMID 11605183·Semin Oncol·2001
6-review
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
PMID 10653877·J Clin Oncol·2000
3-trial
A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer.
PMID 19433964·Am J Clin Oncol·2009
3-trial
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
PMID 19433684·J Clin Oncol·2009
3-trial
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
PMID 19487960·J Thorac Oncol·2009
8-other
Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer.
PMID 19190517·J Thorac Oncol·2009
8-other
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
PMID 19632943·Clin Lung Cancer·2009
3-trial
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.
PMID 18475293·Br J Cancer·2008
3-trial
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
PMID 18936474·J Clin Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1725 W HARRISON ST, SUITE 1010
CHICAGO, IL 60612 - Phone
- (312) 942-5904
Quick Facts
- NPI
- 1235198573
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile